INKT (MiNK Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades
MiNK Therapeutics, Inc. Common Stock (INKT) is a publicly traded Healthcare sector company. As of May 21, 2026, INKT trades at $10.29 with a market cap of $50.02M and a P/E ratio of -3.67. INKT moved +4.15% today. Year to date, INKT is -11.11%; over the trailing twelve months it is +48.60%. Its 52-week range spans $4.56 to $76.00. Analyst consensus is buy with an average price target of $35.00. Rallies surfaces INKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who is trading INKT stock inside the company?
Recent INKT insider activity includes Ryan Barbara sold 300, Ryan Barbara sold 500, Ryan Barbara sold 500, Ryan Barbara sold 200, and Ryan Barbara sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Recent INKT insider activity includes Ryan Barbara sold 300, Ryan Barbara sold 500, Ryan Barbara sold 500, Ryan Barbara sold 200, and Ryan Barbara sold 100. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for INKT?
Yes. Rallies tracks INKT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is INKT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for INKT. It does not provide personalized investment advice.
